CI

At a glance

ClinicalIndex Comparison Record
Phase 3Not Yet Recruiting· 2,508 target
Drug / intervention
4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06996093
NCT06996093Phase 3Not Yet Recruiting
CompareCT.gov

Chemotherapy Omission in Hormone Receptor(HR)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor

Fudan University·interventional·Posted May 30, 2025·Updated May 30, 2025

In Brief

A Phase 3 clinical trial evaluating 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy and aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor for Breast Cancer. Not yet recruiting, targeting 2,508 participants across 1 site.

Detailed Summary

This is a prospective, randomized, open-label, multicenter phase III study to explore chemotherapy omission in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with lymph node negative disease receiving adjuvant endocrine therapy and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--

Timeline

Phase 3Not Yet Recruiting
202620272028202920302031203220332034
First PostedMay 30, 2025
Enrollment StartJun 2, 2025
Primary CompletionJun 1, 2030
Study CompletionJun 1, 2034
TodayJul 1, 2026
Enrollment to primary: 5.0 yearsPosted 1.1 years agoPrimary completion in 3.9 years

Interventions

4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapydrug

4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy

aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitordrug

aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor